Invest Securities maintains its buy rating on OSE Immunotherapeutics shares, with an unchanged target price of 8.2 euros, as the company announced last week that it had secured a 1.5mE loan from Bpifrance to accelerate the development of a companion diagnostic test associated with the Tedopi therapeutic vaccine in lung cancer.

This amount should cover all development costs for the test, whose HLA-A2 methods have already been identified", estimates the analyst, who points out that the launch of the Ph III trial evaluating Tedopi in lung cancer is expected before the end of 2023.

In line with its business model, OSE Immuno plans to conclude an agreement with an industrial partner to partially support the costs of Ph III. Financial visibility to date extends to Q2 2024, which implies a short-term reinforcement", concludes Invest.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.